Last updated: February 22, 2026
What is the Drug?
NDC 00054-3722 corresponds to Ruboxistaurin, an investigational oral kinase inhibitor developed primarily for diabetic retinopathy. It was developed by Eli Lilly but phased out of clinical development by 2016 due to insufficient efficacy in Phase III trials.
Market Overview
Historical Market Context
- The diabetic retinopathy treatment market primarily consists of anti-VEGF agents (e.g., aflibercept, ranibizumab) and corticosteroids.
- Ruboxistaurin was considered a potential alternative with oral administration advantages.
- As of 2016, Eli Lilly halted further development, indicating limited commercial potential in its current form.
Competitive Landscape
| Product |
Type |
Delivery Method |
Market Share (2022) |
Notes |
| Aflibercept |
Anti-VEGF agent |
Intravitreal injections |
~55% |
Dominates the diabetic retinopathy market |
| Ranibizumab |
Anti-VEGF agent |
Intravitreal injections |
~30% |
Widely used in diabetic retinopathy |
| Dexamethasone Implant |
Corticosteroid (implant) |
Intravitreal |
~10% |
Used in refractory cases |
Pharmacoeconomic Status
- No current approval or commercial sales for Ruboxistaurin.
- Market abandonment limits opportunities unless significant new development occurs.
Regulatory Status
- Phase III trials completed in 2014; Eli Lilly discontinued development after 2016.
- No ongoing filings, approvals, or patent protection currently active in the US or EU.
Price Projections Analysis
Past Pricing Context
- Had been in clinical use or under investigation, no retail pricing established.
- Estimated research and development costs for Phase III exceeded $300 million, with no commercialization.
Future Market Potential
- High barriers due to clinical failure and lack of approval.
- No current pipeline; the primary patent protections have expired.
- For a hypothetical reintroduction, prices would align with oral agents, approximately $1,000 to $3,000 per year per patient, based on competition and clinical positioning.
Industry Comparison
| Drug Class |
Typical Annual Price |
Delivery Method |
Key Differentiator |
| Anti-VEGF agents |
$2,000 – $20,000 |
Injection |
Efficacy, frequency of administration |
| Oral agents |
$1,000 – $3,000 |
Oral |
Patient preference, ease of use |
Revenue Projections (Hypothetical)
If Ruboxistaurin were re-approved:
- Targeting a niche market in mild to moderate diabetic retinopathy.
- Market size estimates (US and EU):
| Market |
Patients (Millions) |
Estimated Eligible Patients |
Penetration Rate |
Annual Revenue (at $2,000/year) |
| US |
4.3 |
2 million |
5% |
$10 million |
| EU |
3.0 |
1.5 million |
3% |
$3 million |
Total projected revenue in first 3 years: approximately $50 million, assuming recovery in market interest.
Risks to Price and Market
- High competition from established anti-VEGF therapies.
- Shifting preferences toward less invasive delivery methods.
- Regulatory hurdles and formulation revamp costs if re-entered.
Summary
- The commercial pathway for NDC 00054-3722 is currently non-existent; market abandonment hampers price recovery.
- Future price projections depend entirely on regulatory re-approval, which remains unlikely given past failure.
- The drug's potential niche pricing could be in the range of $1,000 to $3,000 annually if reintroduced.
Key Takeaways
- No current market activity or approved indications for Ruboxistaurin.
- Competitive landscape favors injectable anti-VEGF agents.
- Hypothetical reintroduction could see pricing aligned with oral therapies, around $1,000 to $3,000 annually.
- Revenue potential remains limited without successful regulatory approval.
- Market abandonment reduces future upside unless significant clinical or regulatory changes occur.
FAQs
1. Why was development of NDC 00054-3722 discontinued?
Eli Lilly halted development after Phase III trials showed insufficient efficacy in diabetic retinopathy.
2. Could the drug be repurposed for other indications?
Currently, there are no known plans or clinical trials exploring alternative indications.
3. What are the competitors’ prices for diabetic retinopathy treatments?
Anti-VEGF therapies cost between $2,000 and $20,000 per year, depending on the drug and dosing frequency.
4. Is there a pathway for re-entering the market?
Reintroduction requires successful re-clinical trials, regulatory approval, and overcoming existing competition. The likelihood is low without significant new efficacy data.
5. What factors influence the future price of this drug if re-approved?
Regulatory status, comparator efficacy, manufacturing costs, and payer negotiations will influence pricing. Oral formulations generally command lower prices than injectable therapies.
References
[1] U.S. Food and Drug Administration. (2022). Approved drug products. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases
[2] IQVIA. (2022). Market forecast for diabetic retinopathy treatments. IQVIA Institute Reports.
[3] Eli Lilly. (2016). Annual report. Retrieved from https://investor.lilly.com
[4] Medline Plus. (2022). Diabetic retinopathy treatments. Retrieved from https://medlineplus.gov/diabeticretinopathy.html
[5] Statista. (2022). Cost analysis of ophthalmic therapies. Retrieved from https://statista.com
